Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
about
Stavudine toxicity in adult longer-term ART patients in Blantyre, MalawiCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirThe Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit AnalysisCost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in ZambiaThe macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model.Predictors of Treatment Failure in HIV-Positive Children Receiving Combination Antiretroviral Therapy: Cohort Data From Mozambique and Uganda.Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.Determinants of Mortality among Adult HIV-Infected Patients on Antiretroviral Therapy in a Rural Hospital in Southeastern Nigeria: A 5-Year Cohort Study.HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidenceCost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialMortality along the continuum of HIV care in Rwanda: a model-based analysis.Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.HIV treatment and care in resource-constrained environments: challenges for the next decade.Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulationsFuture of phylogeny in HIV prevention.Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventionsHIV in Africa: Challenges and Directions for the Next Decade.Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.The Cost-effectiveness of a Point-of-Care Paper Transaminase Test for Monitoring Treatment of HIV/TB Co-Infected Persons
P2860
Q28481581-FA897680-CEEF-44F6-BB27-55EC5F2E9B8FQ28482138-6EFA05A9-BD67-4E89-898F-9D89741735D4Q28533242-53CA49CE-6862-4428-8F16-7C5FF98C6A97Q28608172-041F3DBE-0253-480C-A023-ED8A3AA47F89Q30377632-5BFF6F13-E741-45FA-9299-9A22E1D40FCCQ30415562-E98AA9FF-9874-4D00-944C-87B51810DDF9Q30997469-4554BD4C-8098-45CD-809C-F86ECC15C2C3Q33854542-82791AFE-C2A9-419B-898F-5DE966B35D7CQ34073327-F4B82D6E-9D3A-4FB5-B22B-C18B70963A54Q34339471-E3BFD28D-1444-464C-A1B1-97067A3A5F9BQ34526461-1CE23719-78B7-424D-AAA5-CE98A693D1D9Q35854983-9ADF4F46-C9ED-46F2-B7C0-94C37837753FQ36179320-878C57A3-8D3C-4746-8B39-9089C504D5F0Q36209055-50278AAA-3527-41B1-8197-E52FB983727FQ36286145-011E0444-8E51-4975-A8C7-1C9F01F94C25Q36386806-01657A9E-00E4-4896-B14A-A9ACE0738FE3Q36410952-2834A93D-BD01-4920-9B5E-62B246FF17DFQ36945699-3D4B6FC4-004E-48E9-A744-374B48C56482Q37206422-7B83AD67-5C4D-419A-8F39-35F63358D257Q38419599-9BF49959-0DFF-4B37-9BB4-A9F018484BE2Q38861593-8F41E499-2838-409A-9F8D-E76B5099C4BAQ40215127-9117562E-88DC-4069-8410-6DABA1F47A28Q58586061-FAAA04CA-D6FC-45C4-861E-90315D21E18E
P2860
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@ast
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@en
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@nl
type
label
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@ast
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@en
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@nl
prefLabel
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@ast
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@en
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@nl
P2093
P2860
P921
P1433
P1476
Cost-effectiveness of antiretr ...... nes: a South African analysis.
@en
P2093
Andrew Zolopa
Annie Talbot
Douglas K Owens
Eran Bendavid
Philip Grant
P2860
P304
P356
10.1097/QAD.0B013E328340FDF8
P407
P577
2011-01-01T00:00:00Z